These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24628859)

  • 21. Extended-release ranolazine: critical evaluation of its use in stable angina.
    Truffa AA; Newby LK; Melloni C
    Vasc Health Risk Manag; 2011; 7():535-9. PubMed ID: 21915171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting EQ-5D utility scores from the Seattle Angina Questionnaire in coronary artery disease: a mapping algorithm using a Bayesian framework.
    Wijeysundera HC; Tomlinson G; Norris CM; Ghali WA; Ko DT; Krahn MD
    Med Decis Making; 2011; 31(3):481-93. PubMed ID: 21127316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic stable angina is associated with lower health-related quality of life: evidence from Chinese patients.
    Wu J; Han Y; Xu J; Lu Y; Cong H; Zheng J; Sun H
    PLoS One; 2014; 9(5):e97294. PubMed ID: 24842793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
    Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
    Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.
    Keating GM
    Drugs; 2013 Jan; 73(1):55-73. PubMed ID: 23329466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
    Nguyen E; Coleman CI; Kohn CG; Weeda ER
    Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease.
    Goldsmith KA; Dyer MT; Buxton MJ; Sharples LD
    Health Qual Life Outcomes; 2010 Jun; 8():54. PubMed ID: 20525323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder.
    Desroziers K; Aballéa S; Maman K; Nazir J; Odeyemi I; Hakimi Z
    Health Qual Life Outcomes; 2013 Nov; 11():200. PubMed ID: 24246044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on evidence for treatment with ranolazine in stable angina.
    Carbone F; Montecucco F; Mach F
    Swiss Med Wkly; 2013; 143():w13874. PubMed ID: 24163124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
    Willis LH; Slentz CA; Johnson JL; Kelly LS; Craig KP; Hoselton AL; Kraus WE
    Am J Cardiol; 2019 Sep; 124(5):655-660. PubMed ID: 31296368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranolazine in the management of chronic stable angina.
    Zerumsky K; McBride BF
    Am J Health Syst Pharm; 2006 Dec; 63(23):2331-8. PubMed ID: 17106005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
    Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
    Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
    Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
    Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.